Annual General Meeting, Fresenius SE & Co. KGaA

May 20, 2015

Seite 2

2014 Group results

cc = constand currencyEBIT and net income before one-time items

Sales EBIT Net income

Financial Year 2014 €23,231 m €3,158 m €1,086 m

Growth cc +16% +4% +4%

Growth actual rates +14% +4% +3%

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

Seite 3

7.37.9

10.811.4

12.3

14.2

16.0 16.5

19.320.3

23.2

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Sales

11th consecutive record year

€bn

168222

330

410450

514

660

770

938

1.0511.086

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

€bn

Sales Net Income

CAGR 12 % CAGR 21 %

CAGR = annual growth rateNet income before one-time items

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

Seite 4

2014 results for the business segments

FY 2014

SalesUS$15,832 m

+8%€5,146 m

+3%€5,244 m

+55%€1,042 m

+2%

EBITUS$2,255 m

+0%€873 m

-6%€553 m+42%

€59 m+7%

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

Seite 5

Fresenius Group:An excellent start to the new business year

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Sales EBIT Net income

Q1/15 €6,483 m €851 m €292 m

Growth cc +13% +18% +16%

Growth actual rates +24% +32% +28%

cc = constand currencyEBIT and net income before one-time items

Page

Seite 6

0.020.04 0.04

0.05 0.060.07

0.090.10

0.110.13

0.140.15

0.16

0.19

0.220.23

0.25

0.29

0.32

0.37

0.42

0.44

93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14

22nd consecutive dividend increase

Pay-out ratio: 22%

2014: Proposal1993 – 2013: stock split-adjusted

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

In €

Seite 7

The Fresenius share: An attractive long-term investment

0 4 8 12 16 20 24

DAX30

Fresenius share ~20% p.a.

~9% p.a.

%

Compounded annual total return Dec 31, 2004 − Dec 31, 2014

Source: Bloomberg; dividends reinvested

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

Seite 8Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Continuity as an integral part of our corporate culture

Page

Seite 9

Continuity in our values

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Patient focus Quality

Reliability Innovation

Page

Seite 10Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Continuity through long-term strategies:Acquisition of Rhön hospitals

HELIOS 2013

Page

HELIOS 2015

Seite 11Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Continuity through long-term strategies:Fresenius in emerging markets

Page

Seite 12Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Continuity through long-term strategies:From products to therapies

Page

Seite 13Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Our responsibility

Page

Seite 14Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Continuity in management and staff

Page

“Team Fresenius” at the JP Morgan Run in Frankfurt, Germany

Seite 15Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

Steadily increasing demand for healthcare

Page

Seite 16

Outlook for 2015: Fresenius raises guidance

Old New

Revenuein constant currency

+7% to +10%

Net incomein constant currency

+9% to +12% +13% to +16%

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG (~€10 m before tax), before costs for efficiencyprogram at Fresenius Kabi (~€100 m before tax) and disposal gains from the divestment of two HELIOS hospitals (€34 m before tax); 2014 before special items

Page

Seite 17

Fresenius confirms medium-term targets

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015

20.3

23.2

2013 2014 2017

1,0511,086

2013 2014 2017

Sales€bn

Net Income1

€m

1 Before special items

~€30 billion Sales; €1.4 to €1.5 billion Net Income

CAGR 9-11%CAGR 9%~30

~1,400-1,500

+14%

+3%

Page

Seite 18

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Annual General Meeting of Fresenius SE & Co. KGaA © May 20, 2015 Page

Annual General Meeting, Fresenius SE & Co. KGaA

May 20, 2015